Author

Sydney A. Skupa

University of Nebraska Medical CenterORCID 0000-0002-8933-6015Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:metagenomics· 1

Frequent Co-Authors

Audrey L. SmithiD· 2 shared Christopher Robert D'AngeloiD· 2 shared Dalia El‐GamaliD· 2 shared Achyuth KalluchiiD· 1 shared Aguirre A. de CubasiD· 1 shared Akshay KrishnaiD· 1 shared Alexandria P. EikeniD· 1 shared Amarnath NatarajaniD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Audrey L. SmithORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyFrontiers in OncologyPeer-reviewedJul 21, 2026

Impact of high-fat Western diet on chronic lymphocytic leukemia disease progression and gut microbiome profile in Eμ-TCL1 mice

Sydney A. Skupa, Jordan B. Hernandez, Audrey L. Smith…·Dalia El‐Gamal

This study shows that a high-fat Western diet accelerates CLL progression and alters gut microbiome composition in Eμ-TCL1 mice.

DOI 10.3389/fonc.2026.1842275

mousemetagenomics

𝕏 PostBluesky

Cancer BiologyCancer Research CommunicationsPeer-reviewedApr 30, 2024

Novel spirocyclic dimer, SpiD3, targets chronic lymphocytic leukemia survival pathways with potent preclinical effects

Alexandria P. Eiken, Audrey L. Smith, Sydney A. Skupa…·Dalia El‐Gamal

This paper evaluates SpiD3, a novel spirocyclic dimer, showing potent anti-leukemic effects in CLL cells, including resistance to ibrutinib, by targeting NF-κB signaling and the UPR.

2 citations

𝕏 PostBluesky